pCRs were observed in 38/69 (55%) BRCA1 mutation carriers vs. 13/36 (36%) BRCA2-associated cancers (Fisher’s exact test, two-tailed, P = 0.1) or 43/150 (29%) BRCA-WT tumors (Fisher’s exact test, two-tailed, P = 0.0003). This evidence concerns the gene BRCA2 and cancer.